Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies

Abstract

ObjectiveThis study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence.MethodsThrough a search of PubMed, Embase, Web of Science, and CNKI, studies investigating the effectiveness of inactivated COVID-19 vaccines were identified, and a meta-analysis was undertaken to synthesize the vaccine efficacy and effectiveness data. Moreover, a decision-analytic model was developed to estimate the cost-effectiveness of inactivated vaccines for combating the COVID-19 pandemic in the Chinese context from a societal perspective. Results of the meta-analysis, along with cost data from official websites and works of literature were used to populate the model. Sensitivity analysis was performed to test the robustness of the model results.ResultsA total of 24 studies were included in the meta-analysis. In comparison to no immunization, the effectiveness of inactivated vaccine against COVID-19 infection, hospitalization, ICU admission and death were 65.18% (95% CI 62.62, 67.75), 79.10% (95% CI 71.69, 86.51), 90.46% (95% CI 89.42, 91.50), and 86.69% (95% CI 85.68, 87.70); and the efficacy against COVID-19 infection and hospitalization were 70.56% (95% CI 57.87, 83.24) and 100% (95% CI 61.72, 100). Inactivated vaccine vaccination prevented more infections, hospitalizations, ICU admissions, and deaths with lower total costs, thus was cost-saving from a societal perspective in China. Base-case analysis results were robust in the one-way sensitivity analysis, and the percentage of ICU admission or death and direct medical cost ranked the top influential factors in our models. In the probabilistic sensitivity analysis, vaccination had a 100% probability of being cost-effective.ConclusionInactivated vaccine is effective in preventing COVID-19 infection, hospitalization, ICU admission and avoiding COVID-19 related death, and COVID-19 vaccination program is cost-saving from societal perspective in China.

Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study

“…In our study, the VE against hospitalization was 75.7%, which is lower than the 100% reported in clinical trials for preventing COVID-19-related hospitalization and severe infection ( Al Kaabi et al, 2021 ; Tanriover et al, 2021 ). However, this finding is consistent with a recent meta-analysis of nine real-world studies that reported the pooled effectiveness of inactivated vaccines to be 79.10% (95% CI: 71.69 to 86.51) ( Fu et al, 2022 ).…”

Humoral responses after primary and booster SARS‐CoV‐2 inactivated vaccination in patients with chronic hepatitis B virus infection: A longitudinal observational study

“…Inactivated virus vaccines such as BBIBP-CorV (Beijing Institute of Biological Products Co., Beijing, China) and CoronaVac (Sinovac Life Sciences, Beijing, China) have been widely used in China. 9 Our previous cross-sectional study revealed that early antibody responses were lower in patients with CHB than those in healthy controls (HCs) after the second dose of inactivated vaccines (primary vaccination, PV). 10 However, whether the third dose (booster) of inactivated vaccines is likely to improve antibody responses in patients with CHB is currently unknown.…”

Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents

“…To achieve the goal of herd immunity, a variety of vaccines have been introduced worldwide 35 . One of the main vaccines promoted in China is the inactivated virus vaccine, which has a high inoculation coverage among the population up to date 36 .…”